Goal hub

Deep Sleep Architecture

DSIP and related sleep-adjacent peptides. Delta-wave marketing is not a licensed insomnia indication.

Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.

Open full protocolAll goals

Compounds on this goal

DSIP

sleep

Endogenous nonapeptide that increases delta EEG bands (deep sleep). Decreases cortisol, normalizes blood pressure during sleep, and promotes genuine restorative slow-wave architecture without sedative hangover.

Open peptide leaf →

Epitalon

longevity

Resets the pineal gland capacity to synthesize endogenous melatonin at the correct circadian hour, addressing the root cause of age-related melatonin decline rather than providing exogenous supplementation.

Open peptide leaf →

Evidence note on this goal

Protocol evidence level (from existing goal data): Emerging

  • DSIP research peaked in the 1980s-90s; modern controlled trials are extremely limited
  • Neither DSIP nor Epithalon is FDA-approved for any sleep indication
  • DSIP stability in solution is poor (degrades rapidly at room temperature); proper handling critical
  • Some early DSIP studies had methodological limitations that modern review finds insufficient